Publicaciones en las que colabora con Julio Benítez Rodríguez (38)

2004

  1. Farmacogenética

    Velázquez. Farmacología Básica y Clínica (Editorial Médica Panamericana S.A.), pp. 1097-1114

2002

  1. N-acetyltransferase 2 polymorphism is not related to the risk of advanced alcoholic liver disease

    Scandinavian Journal of Gastroenterology, Vol. 37, Núm. 1, pp. 99-103

  2. N-acetyltransferase 2 single-nucleotide polymorphisms and risk of gastric carcinoma

    Cancer Chemotherapy and Pharmacology, Supplement, Vol. 49, Núm. 7, pp. 115-118

  3. Single nucleotide polymorphisms and microsatellite alleles of tumor necrosis factor alpha and interleukin-10 genes and the risk of advanced chronic alcoholic liver disease

    Liver, Vol. 22, Núm. 3, pp. 245-251

2001

  1. Functionally active duplications of the CYP2D6 gene are more prevalent among larynx and lung cancer patients

    Oncology, Vol. 61, Núm. 1, pp. 59-63

2000

  1. N-acetyltransferase 2 (NAT2) genotype and colorectal carcinoma: Risk variability according to tumour site?

    Scandinavian Journal of Gastroenterology, Vol. 35, Núm. 10, pp. 1087-1091

1998

  1. Expression in human prostate of drug- and carcinogen-metabolizing enzymes: Association with prostate cancer risk

    British Journal of Cancer, Vol. 78, Núm. 10, pp. 1361-1367

  2. Polimorfismos enzimáticos y cáncer de pulmón

    Medicina Clinica, Vol. 111, Núm. 12, pp. 465-470

  3. Slow allotypic variants of the NAT2 gene and susceptibility to early- onset Parkinson's disease

    Neurology, Vol. 51, Núm. 6, pp. 1587-1592

1997

  1. CYP2A6 gene polymorphism and risk of liver cancer and cirrhosis

    Pharmacogenetics, Vol. 7, Núm. 3, pp. 247-250

  2. CYP2D6, NAT2 and CYP2E1 genetic polymorphisms in nonagenarians

    Age and Ageing, Vol. 26, Núm. 2, pp. 147-151

  3. Polymorphism is not associated with essential tremor

    European Neurology, Vol. 38, Núm. 2, pp. 99-104

1996

  1. CYP2D6 genotypes in Spanish women with breast cancer

    Cancer Letters, Vol. 99, Núm. 1, pp. 23-28

  2. Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white population

    Pharmacogenetics, Vol. 6, Núm. 5, pp. 423-428

  3. Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers

    Pharmacogenetics, Vol. 6, Núm. 6, pp. 501-512

  4. Rsa I polymorphism at the cytochrome P4502E1 locus is not related to the risk of alcohol-related severe liver disease

    Liver, Vol. 16, Núm. 6, pp. 380-383

  5. RsaI polymorphism at the cytochrome P4502E1 locus and risk of hepatocellular carcinoma

    Gut, Vol. 39, Núm. 2, pp. 330-333

1995

  1. Association between the oxidative polymorphism and early onset of Parkinson's disease

    Clinical Pharmacology and Therapeutics, Vol. 57, Núm. 3, pp. 291-298

  2. CYP2D6 genes and risk of liver cancer

    The Lancet, Vol. 345, Núm. 8953, pp. 830-831

  3. Debrisoquine oxidation polymorphism in patients with chronic inflammatory bowel disease

    Annals of Medicine, Vol. 27, Núm. 5, pp. 555-558